Correct:) There is Zero reason to react or over react at the 10 Q being late. We just saw the 10 K days ago and the fact is the 10 Q WILL Be released. This is the Beginning of the Beginning of a Potential Revenue Turnaround and the cleaning up of balance sheet/ Reorganizing. The PR's show consistent news flow of collaborations and partnerships and the new research division being formed and IND's and with time the patents will be approved, the Revenues will begin and the latter part of the proclaimed 12 month vision of starting clinics will manifest. The needed shift in management and execution focus by additional leadership will be soon forthcoming and all will start to fall in place. A lot is happening in the background and this isnt a simple task. There are definitely potentially Positive revenue creating developments , some of which could translate quicker than others into Revenues and once revenues start flowing and additional partnerships are announced possibly in Q3 and Q4 , the PPS will have moved up from these low levels.
The downside of .003 is quantifiably and definitively measurable. The upside given the looming International patent approval, the announcement of senior management potentially changing to directly benefit the bottom financial impact with a seasoned CFO ( to be seen ), the revenue flow from andrews starting at some point if not already on the books that we may not know of sometime during this second quarter and so on causes one to reasonably believe that the upside may be justifiably over time a lot higher.
For High Risk Investors this is a time to Buy, Hold and Accumalate IMO ONLY
JUST IMO
News 
Market Data 
Discover 
AI
